Silver Book Fact

Flu causes close to 1/2 of lost workdays and low productivity in adults 50-64 during flu season

During influenza season, influenza-like-illness is responsible for 45% of workdays lost and for 49% of low productivity days among working adults aged 50–64 years.

Nichol, Kristin L., Sarah J. D'Heilly, Michael E. Greenberg, and Edward Ehlinger. Burden of Influenza-like Illness and Effectiveness of Influenza Vaccination Among Working Adults Aged 50-64 Years. Clin Infect Dis. 2009; 48(3): 292-8. http://cid.oxfordjournals.org/content/48/3/292.long

Reference

Title
Burden of Influenza-like Illness and Effectiveness of Influenza Vaccination Among Working Adults Aged 50-64 Years
Publication
Clin Infect Dis
Publication Date
2009
Authors
Nichol, Kristin L., Sarah J. D'Heilly, Michael E. Greenberg, and Edward Ehlinger
Volume & Issue
Volume 48, Issue 3
Pages
292-8
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Sepsis hospitalization rate increases with age
    The rate of hospitalization for sepsis/septicemia in 2008 was around 30 times higher for patients ages 85 and older, than for those under the age of 65.  
  • Tremendous impact of flu epidemics
    Flu epidemics in the U.S. lead to approximately: 600,000 life years lost 3,000,000 days of hospitalization 30,000,000 outpatient visits 48,000 deaths  
  • Hospitalization rates in shingles patients rises with age
    Hospitalization rates for people with shingles are 75 times higher for people age 85+ than for those under the age of 30.  
  • Unplanned Hospital Readmissions & Costs Following Sepsis Hospitalizations
    Among 187,697 hospital admissions for medical reasons that were associated with an unplanned 30-day readmission,  147,084 had a diagnosis of sepsis, 15,001 had a diagnosis of AMI, 79,480 were diagnosed with heart failure, 54,396…  
  • Drug-resistant MRSA expensive to treat
    As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.